TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01585766
Drug: PLACEBO-IV-SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1
Study: NCT01585766
Drug: MEDI-551 300 MG-SC
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received SC injection of 300 mg MEDI-551 on Day 1.
Study: NCT01502644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching oxycodone, placebo-matching morphine
Study: NCT00203450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill
Study: NCT02690961
Drug: Kukoamine B Mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
Study: NCT02690961
Drug: placebo multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01701258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-dose placebo capsule during the fMRI session only
Study: NCT00177424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets
Study: NCT02733380
Drug: Liposomal Doxorubicin or mitoxantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/m2, IV on day 1 of each 14 day cycle（Note：for patients who can not afford the liposomal doxorubicin，may be replaced into mitoxantrone 8mg/m2, IV on day1 of each 14 day cycle） until disease progression or unacceptable toxicity develops, up to 12 cycles
Study: NCT00706862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, twice per day
Study: NCT02000765
Drug: GSK2140944 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2140944 (1 gram) for Injection will be supplied as powder for injection containing \[14C\] GSK2140944. Non sterile powder is to be dissolved aseptically in sterile water for injection to a concentration of 4 mg/mL free base equivalent. IV solution is prepared by sterile filtration. 250 mL of IV solution, equivalent to 1000 mg GSK2140944, is then administered intravenously.
Study: NCT02000765
Drug: GSK2140944 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2140944 Capsule (2 gram) will be supplied as powder in capsule containing \[14C\] GSK2140944. Powder is to be filled in empty capsule to achieve 200-400 mg strength per capsules as free base equivalent. Sufficient capsules are administered to provide the required total dose of 2 gram as free base.
Study: NCT00759525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for fourteen days
Study: NCT01778920
Drug: EC17 imaging contrast agent
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
Study: NCT00605891
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pMDI once a day, in the morning (1 puff of placebo pMDI + 1 puff of placebo pMDI)
Study: NCT00958737
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 or 12 treatments of FOLFOX (FOLFOX4 or modified FOLFOX6 (mFOLFOX6))
Study: NCT00958737
Drug: CAPOX
Normalized name: Capecitabine and Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 or 8 cycles
Study: NCT04070495
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28
Study: NCT02182271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01252524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet po TID before each meal with 8 oz of water for 6 months
Study: NCT01482104
Drug: MAL-PDT re-treatment
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months
Study: NCT01482104
Drug: usual MAL-PDT
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.
Study: NCT02948842
Drug: Clostridium Histolyticum Collagenase
Normalized name: Clostridium histolyticum collagenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture. This is based on 0.25 mL residual fluid that remains within the lumen of the injeTAK syringe. Thus, by adding the additional 0.25 mL of XIAFLEX® as a chase, we are expecting the original total of 0.08 mL of XIAFLEX® to be injected into the area of scarring.
Study: NCT01018459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.
Study: NCT02165111
Drug: sterile saline solution
Normalized name: Blairex Sterile Saline Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01440946
Drug: rFIXFc
Normalized name: rFIXFc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vials of rFIXFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
Study: NCT03594591
Drug: Antidiabetic treatment by usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation of changes in the microcirculation after optimization of antidiabetic therapy by usual care.
Study: NCT01211275
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
Study: NCT00101101
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
Study: NCT00101101
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
Study: NCT04519658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets by mouth once daily
Study: NCT00799149
Drug: Gabapentin, Etoricoxib, Sugar pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .
Study: NCT01357993
Drug: JNS001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
Study: NCT01934634
Drug: LCL161
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCL161 (tablets): 300, 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days
Study: NCT01848990
Drug: Commercial Hylenex® recombinant (hyaluronidase human injection)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02136875
Drug: Self-administered prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: An Acute Exacerbation of COPD (AECOPD) is defined as a sustained worsening of dyspnea, cough or sputum production leading to an increase in the use of maintenance medication and/or supplementation with additional medication. In addition, exacerbations should be defined as either purulent or non-purulent.~Standing prescriptions for exacerbation:~1) Purulent exacerbation - Antibiotic: Avelox 400 mg daily for 5 days. 2a) Mild to moderate exacerbation - Combination therapy (SFP - Advair) to be increased as follows: If regular treatment is Advair 250/50 BID then dose should be increased to Advair 500/100 BID for 10 days; if regular treatment is Advair 500/50 BID then increase to Advair 1000/100 BID for 10 days.~2b) Severe exacerbation - Prednisone (oral): 40 mg once daily for 7-10 days
Study: NCT00647621
Drug: Extended Phenytoin Sodium Capsules 100 mg
Normalized name: phenytoin sodium Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
Study: NCT00647621
Drug: Dilantin® Kapseals® 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
Study: NCT00650039
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, placebo BID by mouth on Days 2 to 5.
Study: NCT00650039
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg once daily (QD) by mouth on Days 2 to 5.
Study: NCT00650039
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg twice daily (BID) by mouth on Days 2 to 5.
Study: NCT02423265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo: up-titration after 1 week
Study: NCT01486017
Drug: ASP015K
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00917813
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1 - Physiological saline IV on Days 1, 8, and 15; Cohort 2 - Physiological saline IV on Days 1, 8, and 15; Cohort 3 - Physiological saline IV on Days 1, 8, and 15
Study: NCT02379585
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
Study: NCT02379585
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
Study: NCT00963729
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00963729
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02447991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.
Study: NCT01242904
Drug: bimodal solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL of 30% glucose infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
Study: NCT02932397
Drug: Intravenous dose of 0.05 mL/kg of saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04465175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (2.5 ml/kg) infusion over one hour
Study: NCT00568308
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo
Study: NCT04346615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Q8h for 14 days
Study: NCT00002604
Drug: chemosensitization/potentiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03475160
Drug: Placebo vaginal suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
Study: NCT00194012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addressed in arm description.
Study: NCT00218062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00864500
Drug: Clobex TM 0.05% Lotion, single exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: B:Active Comparator Subjects received Galderma Laboratories, L.P. formulated products
Study: NCT01326780
Drug: 1.2% JNJ 10229570-AAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks
Study: NCT01326780
Drug: 2.4% JNJ 10229570-AAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks
Study: NCT01326780
Drug: 3.6% JNJ 10229570-AAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks
Study: NCT00274716
Drug: MK0736
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00274716
Drug: MK0916
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00274716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04031885
Drug: Standard Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy of physician's choice administered according to product label.
Study: NCT01648777
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Isotonic NaCl solution (9°/00) solution: for the intravenous bolus of 10 ml~* Isotonic NaCl solution (9°/00) solution, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00
Study: NCT00854087
Drug: Fuzheng Huayu
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will be taking 2 tablets three times a day for 48 weeks.
Study: NCT00854087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will be taking 2 tablets three times a day for 48 weeks.
Study: NCT00145509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-dissolving tablet; twice daily (BID) sublingually for 40 weeks
Study: NCT02922452
Drug: Dilitazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose BMS-986141 and Multiple doses of Dilitazem
Study: NCT01341184
Drug: TMC207
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC207 400 mg orally on days 1 and 29
Study: NCT00394966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
Study: NCT03354429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.
Study: NCT02285985
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets: 5mg
Study: NCT04537806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as IV infusion.
Study: NCT02477020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-063 matching-placebo tablet.
Study: NCT02845271
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular
Study: NCT02845271
Drug: GZ389988
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:suspension for injection~Route of administration: intraarticular
Study: NCT02845271
Drug: acetaminophen or paracetamol
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02845271
Drug: fixed combination of paracetamol + codeine
Normalized name: codeine and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT02285751
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03536728
Drug: AMXT1501
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 40 mg or 200 mg (free base content) enterically-coated capsules
Study: NCT02566759
Drug: TAK-831 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-831 placebo-matching oral suspension.
Study: NCT01061060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01034397
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv every 4 weeks for 24 weeks
Study: NCT01034397
Drug: non-biological DMARDs
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: stable dose at investigator's prescription
Study: NCT00963664
Drug: lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals
Study: NCT04480710
Drug: CRV431 75mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 75mg softgel capsule
Study: NCT04480710
Drug: Placebo (1 softgel)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x placebo softgel capsule
Study: NCT04480710
Drug: CRV431 225mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 75mg softgel capsule
Study: NCT02205892
Drug: Placebo vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are supposed to apply their control vehicle cream two times per day to the other side of their face for 4 weeks. Application side is randomly determined.
Study: NCT00004026
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02942654
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (SC)
Study: NCT01777945
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received capecitabine according to individualized physician-prescribed regimen.
Study: NCT03598751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL
Study: NCT00238459
Drug: Patients elected to take licensed drugs. The vaccine was not provided for evaluation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Note:In August 2007 we were notified by the manufacturer that the experimental vaccine was no longer being made and would no longer be available for this study. Too few participants have received the vaccine or placebo to conclude anything about potential efficacy
Study: NCT00238459
Drug: multiple licensed antiretroviral drugs; not randomized
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03067376
Drug: [14C]-CORT125134
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03677297
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel
Study: NCT04233814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo is micronized lactose powder administered by inhalation through a dry powder inhaler.
Study: NCT00399399
Drug: azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00399399
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01406015
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg once daily for 6 weeks.
Study: NCT01406015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching spironolactone once daily for 6 weeks.
Study: NCT01896583
Drug: ASP7147
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg, tablet, twice per day for 4 weeks oral
Study: NCT01896583
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03652467
Drug: Conventional TACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemoembolization drugs are injected through hepatic artery.
Study: NCT00982189
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized to take pravastatin (active) or matching placebo pill once daily
Study: NCT02074735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredient matching the active comparator in appearance
Study: NCT03669081
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
Study: NCT03669081
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule was administered orally 30 minutes prior to operation.
Study: NCT00578773
Drug: Moxidex otic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Study: NCT01337258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men taking placebo daily
Study: NCT01789216
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01732913
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally twice daily
Study: NCT04166318
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04166318
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV